Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Volume 13 Issue 4, April 2016

Cover image supplied by S. Ferreira-Gonzalez and S.J. Forbes, MRC Centre for Regenerative Medicine, Edinburgh, UK, who are funded by MRC and Principal’s Career Development Edinburgh University grants. Immunofluorescence image of ductular reaction in the liver. Tissue was stained to show marker of biliary differentiation keratin 19 (rat anti-troma III) and red fluorescent protein (rabbit anti-RFP). Nuclei were stained by DAPI.

Research Highlight

Top of page ⤴

Erratum

Top of page ⤴

Research Highlight

Top of page ⤴

In Brief

Top of page ⤴

Research Highlight

Top of page ⤴

News & Views

  • The recently released UK Chief Medical Officers Alcohol Guidelines Review set up new restricted limitations in alcohol consumption—14 units, the same amount for both men and women. In parallel, the popular Dry January campaign was launched again, aimed at promoting prolonged abstinence. Are these campaigns enough to give up boozing?

    • Joaquin Cabezas
    • Ramon Bataller
    News & Views
  • Eosinophilic oesophagitis (EoE) is a clinicopathological condition. In addition to drugs and diets, dilation is an established treatment modality. Although the procedure was once considered risky, results from a new study add to the evidence that oesophageal dilation can be considered a safe and effective intervention to relieve dysphagia, the primary symptom of EoE.

    • Alex Straumann
    • Alain Schoepfer
    News & Views
  • A recent study demonstrated that drug–drug interactions are common in patients with HCV and are a challenge for treatment. Identification of these interactions can be time-consuming and complex. A multidisciplinary approach to HCV treatment, including a clinical pharmacist, can help identify and manage HCV drug interactions.

    • Jacob A. Langness
    • Gregory T. Everson
    News & Views
Top of page ⤴

Review Article

  • NAFLD is a leading cause of chronic liver disease worldwide. This Review discusses the diagnosis and stratification of patients with NAFLD by disease stage, and provides a stage-based approach to treatment. Pharmaceuticals in advanced development and potential future therapeutics are also addressed.

    • Mary E. Rinella
    • Arun J. Sanyal
    Review Article
  • Clostridium difficileinfection (CDI) is a global health-care problem and represents an important infection in both health-care facilities and the wider community. Here, the authors describe advances in understanding of CDI epidemiology, transmission and diagnosis, which are all key factors in the management of CDI.

    • Jessica S. H. Martin
    • Tanya M. Monaghan
    • Mark H. Wilcox
    Review Article
  • The use of laparoscopic techniques to treat benign and malignant pancreatic disease is becoming more common, but the benefits or limitations in comparison with conventional surgery are not fully clear as yet. Here, an overview of all the high-quality data to date on laparascopic is comprehensively assessed with a focus on laparoscopic Whipple and laparoscopic distal pancreatectomy.

    • Thijs de Rooij
    • Sjors Klompmaker
    • Marc G. Besselink
    Review Article
Top of page ⤴

Opinion

  • The many gaps in our knowledge and understanding of HBV infection hampers our ability to develop and achieve a cure on a global scale. In this Perspective, Fabien Zoulim and colleagues propose the development of an international group consisting of four working groups (virology, immunology, innovative tools and clinical trials) to tackle the big questions and make important steps towards eradicating this disease.

    • Peter Revill
    • Barbara Testoni
    • Fabien Zoulim

    Collection:

    Opinion
Top of page ⤴

Search

Quick links